Enanta Pharmaceuticals | ENTA - Selling And Administration Expenses


Enanta Pharmaceuticals reported $-1.05 in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Incyte USD 351.73M 23.64M Jun/2026
Insmed USD 247.47M 208K Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
J&J USD 6.25B 168M Sep/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
Merck USD 2.89B 219M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026